Docetaxel (Taxotere®) plus cisplatin: An active and well-tolerated combination in patients with advanced non-small cell lung cancer

European Journal of Cancer

Volumn 34, Issue 13, 1998, Pages 2032-2036

  Le Chevalier, T ^a   Monnier, A ^c   Douillard, J Y ^c   Ruffle, P ^a   Sun, X S ^c   Belli, L ^a   Ibrahim, N ^c   Bougon, N ^b   Berille J ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b SANOFI   (France)

^c NONE

Author keywords

Cisplatin; Docetaxel; Non small cell lung cancers phase II study

Indexed keywords

CETIRIZINE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ONDANSETRON; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; PACLITAXEL; TAXOID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; THROMBOCYTOPENIA; ADOLESCENT; CHEMICALLY INDUCED DISORDER; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 0032249677     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00287-1     Document Type: Article

References (21)

1. 1. Ginsberg RJ, Yokes EE, Raben A. Non small cell lung cancer. In DeVita VT, Hellman S, Rosenberg SA, eds. Principles and Practice in Oncology, 5th ed. Philadelphia, Lippincott-Raven, 1997, 858-911.
2. 2. Feigal EG, Chriatian M, Cheson B, Grever M, Friedman MA. New chemotherapeutic agents in non-small-cell-lung cancer. Semin Oncol 1993, 20, 185-201.
3. 3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995, 311, 899-909.
4. 4. Edelman MJ, Gandara DR. Promising new agents in the treatment of non small cell lung cancer. Cancer Chemother Pharmacol 1996, 37, 385-393.
5. ®), an active agent in the first and second line treatment of advanced non small cell lung cancer. Semin Oncol 1995, 22(Suppl. 4), 22-29.
6. 6. Von Hoff DD. Toxic effects of cisdichlorodiammineplatinum (II) in man. Cancer Treat Rep 1979, 63, 1526-1531.
7. 7. Millward MJ, Zalcberg J, Bishop JF, et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non small cell lung cancer. J Clin Oncol 1997, 15, 750-758.
8. 8. Bunn PA. The treatment of non small cell lung cancer: current perspectives and controversies. Future directions. Semin Oncol 1994, 21(3), 49-59.
9. ®): a review of preclinical and clinical experience. Part 1: preclinical experience. Anticancer Drugs 1995, 6, 339-368.
10. 10. World Health Organization. The World Health Organization Histological Typing of Lung Tumors. Second Edition. Am J Clin Pathol 1982, 77, 123-136.
11. 11. Fleming T. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38, 143-151.
12. 12. Cole JT, Gralla RJ, Marques CB, Rittenberg CN. Phase I-II study of cisplatin + docetaxel (Taxotere) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995, 14, 357 (abstract 1087).
13. 13. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994, 12, 360-367.
14. 14. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide-cisplatin versus taxol with cisplatin-granulocyte colony stimulating factor versus taxol-cisplatin in advanced non small cell lung cancer: an Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 1996, 15, 382 (abstract 1145).
15. 15. Giaccone G, Splinter T, Postmus P, et al. Paclitaxel-cisplatin versus teniposide-cisplatin in advanced non small cell lung cancer. Proc Am Soc Clin Oncol 1996, 15, 373 (abstract 1109).
16. 16. Sandler A, Crino L, Steward WP, Abratt RP. Extended survival in stage III and IV non small cell lung cancer (NSCLC) patients treated with gemcitarabine plus monthly cisplatin. Ann Oncol 1996, 7(Suppl. 5), 91 (abstract 435P).
17. 17. Mosconi AM, Crino L, Tonato M. Combination therapy with gemcitarabine in non small cell lung cancer. Eur J Cancer 1997, 33(Suppl. 1), 14-17.
18. 18. Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitarabine combination in advanced non small cell lung cancer: a phase II study. J Clin Oncol 1997, 15, 297-303.
19. 19. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized phase III trial of cisplatin versus cisplatin plus navelbine in treatment of advanced non small cell lung cancer: report of a Southwest Oncology Group study. Proc Am Soc Clin Oncol 1996, 15, 374 (abstract 1110).
20. 20. Rapp E, Pater JL, Villan A, et al. Chemotherapy can prolong survival in patients with advanced non small cell lung cancer. Report of the Canadian multicenter randomized trial. J Clin Oncol 1988, 6, 633-641.
21. 21. Zalcberg JR, Bishop JF, Millward MJ, et al. Preliminary results of the first phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1995, 14, 351 (abstract 1062).